Literature DB >> 19698751

The efficiency of single genome amplification and sequencing is improved by quantitation and use of a bioinformatics tool.

David M Butler1, Mary E Pacold, Parris S Jordan, Douglas D Richman, Davey M Smith.   

Abstract

Typically, population-based sequencing of HIV does not detect minority variants present at levels below 20-30%. Single genome amplification (SGA) and sequencing improves detection, but it requires many PCRs to find the optimal terminal dilution to use. A novel method for guiding the selection of a terminal dilution was developed and compared to standard methods. A quantitative real-time PCR (qRT-PCR) protocol was developed. HIV RNA was extracted, reverse transcribed, and quantitated. A bioinformatics web-based application was created for calculating the optimal concentration of cDNA to use based on results of a trial PCR using the dilution suggested by the qRT-PCR results. This method was compared to the standard. Using the standard protocol, the mean number of PCRs giving an average of 30 (26-34, SD=3) SGA per sample was 245 (218-266, SD=20) after an average of 8 trial dilutions. Using this method, 135 PCRs (135-135, SD=0) produced 30 (27-30, SD=1) SGA using exactly two dilutions. This new method reduced turnaround time from 8 to 2 days. Standard methods of SGA sequencing can be costly and both time- and labor-intensive. By choosing a terminal dilution concentration with the proposed method, the number of PCRs required is decreased and efficiency improved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19698751      PMCID: PMC2761514          DOI: 10.1016/j.jviromet.2009.08.002

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  12 in total

1.  Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples.

Authors:  H F Günthard; J K Wong; C C Ignacio; D V Havlir; D D Richman
Journal:  AIDS Res Hum Retroviruses       Date:  1998-07-01       Impact factor: 2.205

2.  Minimizing DNA recombination during long RT-PCR.

Authors:  G Fang; G Zhu; H Burger; J S Keithly; B Weiser
Journal:  J Virol Methods       Date:  1998-12       Impact factor: 2.014

3.  DNA recombination during PCR.

Authors:  A Meyerhans; J P Vartanian; S Wain-Hobson
Journal:  Nucleic Acids Res       Date:  1990-04-11       Impact factor: 16.971

4.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

5.  Long polymerase chain reaction amplification of heterogeneous HIV type 1 templates produces recombination at a relatively high frequency.

Authors:  Y L Yang; G Wang; K Dorman; A H Kaplan
Journal:  AIDS Res Hum Retroviruses       Date:  1996-03-01       Impact factor: 2.205

6.  Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1.

Authors:  P Simmonds; P Balfe; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Authors:  Sarah Palmer; Mary Kearney; Frank Maldarelli; Elias K Halvas; Christian J Bixby; Holly Bazmi; Diane Rock; Judith Falloon; Richard T Davey; Robin L Dewar; Julia A Metcalf; Scott Hammer; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

8.  Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.

Authors:  P Simmonds; P Balfe; J F Peutherer; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

9.  Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing.

Authors:  Jesus F Salazar-Gonzalez; Elizabeth Bailes; Kimmy T Pham; Maria G Salazar; M Brad Guffey; Brandon F Keele; Cynthia A Derdeyn; Paul Farmer; Eric Hunter; Susan Allen; Olivier Manigart; Joseph Mulenga; Jeffrey A Anderson; Ronald Swanstrom; Barton F Haynes; Gayathri S Athreya; Bette T M Korber; Paul M Sharp; George M Shaw; Beatrice H Hahn
Journal:  J Virol       Date:  2008-02-06       Impact factor: 5.103

10.  Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.

Authors:  Jeffrey A Johnson; Jin-Fen Li; Xierong Wei; Jonathan Lipscomb; David Irlbeck; Charles Craig; Amanda Smith; Diane E Bennett; Michael Monsour; Paul Sandstrom; E Randall Lanier; Walid Heneine
Journal:  PLoS Med       Date:  2008-07-29       Impact factor: 11.069

View more
  14 in total

1.  Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.

Authors:  Sara Gianella; Wayne Delport; Mary E Pacold; Jason A Young; Jun Yong Choi; Susan J Little; Douglas D Richman; Sergei L Kosakovsky Pond; Davey M Smith
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Identifying and characterizing recently transmitted viruses.

Authors:  Brandon F Keele
Journal:  Curr Opin HIV AIDS       Date:  2010-07       Impact factor: 4.283

3.  Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12.

Authors:  Jianhui Nie; Juan Zhao; Qingqing Chen; Weijin Huang; Youchun Wang
Journal:  Virol Sin       Date:  2014-09-28       Impact factor: 4.327

4.  Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment.

Authors:  George K Hightower; Joseph K Wong; Scott L Letendre; Anya A Umlauf; Ronald J Ellis; Caroline C Ignacio; Robert K Heaton; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; J A McCutchan; Igor Grant; Susan J Little; Douglas D Richman; Sergei L Kosakovsky Pond; Davey M Smith
Journal:  Virology       Date:  2012-09-20       Impact factor: 3.616

5.  HIV migration between blood plasma and cellular subsets before and after HIV therapy.

Authors:  Jun Yong Choi; Antoine Chaillon; Jin Ok Oh; Jin Young Ahn; Hae Won Ann; In Young Jung; Mi-Young Ahn; Yong Duk Jeon; Nam Su Ku; Davey M Smith; June Myung Kim
Journal:  J Med Virol       Date:  2015-09-21       Impact factor: 2.327

Review 6.  Phylogenetics and Phyloanatomy of HIV/SIV Intra-Host Compartments and Reservoirs: The Key Role of the Central Nervous System.

Authors:  Marco Salemi; Brittany Rife
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.341

7.  Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.

Authors:  Teresa H Evering; Saurabh Mehandru; Paul Racz; Klara Tenner-Racz; Michael A Poles; Amir Figueroa; Hiroshi Mohri; Martin Markowitz
Journal:  PLoS Pathog       Date:  2012-02-02       Impact factor: 6.823

8.  The relatedness of HIV epidemics in the United States-Mexico border region.

Authors:  Sanjay R Mehta; Wayne Delport; Kimberly C Brouwer; Stephen Espitia; Thomas Patterson; Sergei Kosakovsky Pond; Steffanie A Strathdee; Davey M Smith
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-26       Impact factor: 1.723

9.  Comparison of methods to detect HIV dual infection.

Authors:  Mary Pacold; Davey Smith; Susan Little; Pok Man Cheng; Parris Jordan; Caroline Ignacio; Douglas Richman; Sergei Kosakovsky Pond
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-18       Impact factor: 1.723

10.  A New Method for Rapid Screening of End-Point PCR Products: Application to Single Genome Amplified HIV and SIV Envelope Amplicons.

Authors:  Laurent Houzet; Claire Deleage; Anne-Pascale Satie; Laetitia Merlande; Dominique Mahe; Nathalie Dejucq-Rainsford
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.